Analyzing...
Loading company...
Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 7,713 full-time employees. The company went IPO on 2000-06-05. The firm provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The firm is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. The company has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The firm's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹5,453 Cr revenue.
COGS 21.7%, employees 23.7%.
“revenue from the operations grew by 20%”
“registering an excellent growth of 22%.”
“mid teens growth for the whole year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 23.3%▲ | 10.3% |
| ROCE | 29.4%▲ | 13.7% |
| Net Margin | 18.8%▲ | 7.6% |
| EBITDA Margin | 27.9%▲ | 15.4% |
| Debt To Equity | 0.05x▼ | 0.15x |
| Rev Growth 3yr | 13.6%▲ | 10.0% |
| EPS Growth 3yr | 22.6%▲ | 16.0% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹5,776 Cr +24.3% | ₹4,648 Cr +10.4% | ₹4,209 Cr +12.5% | ₹3,743 Cr +12.0% | ₹3,341 Cr +15.6% | ₹2,890 Cr +11.7% | ₹2,588 Cr +25.9% | ₹2,055 Cr |
| Other Income | ₹217 Cr +129.2% | ₹95 Cr +11.7% | ₹85 Cr -14.2% | ₹99 Cr -14.7% | ₹116 Cr +345.3% | ₹26 Cr -71.8% | ₹92 Cr +337.3% | ₹21 Cr |
| Total Income | ₹5,993 Cr +26.4% | ₹4,743 Cr +10.5% | ₹4,293 Cr +11.8% | ₹3,841 Cr +11.1% | ₹3,457 Cr +18.6% | ₹2,916 Cr +8.8% | ₹2,680 Cr +29.1% | ₹2,076 Cr |
| COGS | ₹1,236 Cr +15.4% | ₹1,071 Cr +0.4% | ₹1,067 Cr +1.5% | ₹1,050 Cr +26.2% | ₹832 Cr +29.0% | ₹645 Cr -1.6% | ₹656 Cr +71.0% | ₹383 Cr |
| ₹4,499 Cr +26.6% | ₹3,553 Cr +11.8% | ₹3,179 Cr +2.7% | ₹3,096 Cr +21.5% | ₹2,547 Cr +26.4% | ₹2,015 Cr +0.2% | ₹2,012 Cr +28.8% | ₹1,562 Cr | |
| Profit Before Tax | ₹1,493 Cr +25.6% | ₹1,189 Cr +6.8% | ₹1,114 Cr +49.5% | ₹745 Cr -18.1% | ₹909 Cr +1.0% | ₹900 Cr +35.6% | ₹664 Cr +29.1% | ₹514 Cr |
| ₹358 Cr +33.4% | ₹269 Cr -9.7% | ₹298 Cr +89.3% | ₹157 Cr -20.1% | ₹197 Cr -20.1% | ₹246 Cr +25.5% | ₹196 Cr +54.2% | ₹127 Cr | |
| Net Profit | ₹1,135 Cr +23.3% | ₹920 Cr +12.8% | ₹816 Cr +38.8% | ₹588 Cr -17.5% | ₹713 Cr +9.0% | ₹654 Cr +39.8% | ₹468 Cr +20.9% | ₹387 Cr |
| Profit (Owners) | ₹1,135 Cr +23.3% | ₹920 Cr +12.8% | ₹816 Cr +38.8% | ₹588 Cr -17.5% | ₹713 Cr +9.0% | ₹654 Cr +39.8% | ₹468 Cr +20.9% | ₹387 Cr |
| Other Comprehensive Income | ₹25 Cr | ₹2 Cr +128.4% | ₹0.81 Cr -94.5% | ₹15 Cr ↑ Recovery | (₹8 Cr) -23.6% | (₹6 Cr) ↓ Decline | ₹6 Cr ↑ Recovery | (₹3 Cr) |
| EPS | ₹90.84 | ₹73.68 | ₹64.82 | ₹45.89 | ₹55.62 | ₹50.38 | ₹35.73 | ₹29.57 |
| Diluted Shares | ₹12 Cr | ₹12 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Ajanta Pharma Limited has informed the Exchange about Link of Recording
Ajanta Pharma Limited has informed the Exchange about ESOP Allotment
Ajanta Pharma Limited has informed the Exchange that Board of Directors at its meeting held on July 30, 2026, declared Select Dividend of Rs. 32 per equity share.
Ajanta Pharma Limited has informed the Exchange that Record date for the purpose of Dividend is 05-Aug-2026.
Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Ajanta Pharma Limited has informed the Exchange about Schedule of meet
Ajanta Pharma Limited has informed the Exchange about Schedule of meet
Ajanta Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 16, 2026. Further, the company has informed the Exchange regarding voting results.
Ajanta Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 16, 2026
Ajanta Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Ajanta Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 16, 2026
Ajanta Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Ajanta Pharma Limited has informed the Exchange about Shareholders Meeting- 47th Annual General Meeting on 16/07/2026